Glaukos price target raised to $86 from $83 at BTIG

BTIG analyst Ryan Zimmerman raised the firm’s price target on Glaukos to $86 from $83 and keeps a Buy rating on the shares. The analyst cites the advancement of the company’s pipeline continuing on track with rapid enrollment in the Epoxia confirmatory Phase 3 trial and preparations for the iDose launch. Given the reimbursement updates through Q2, iStent infinite looks to be a growing contributor and source of upside in the second half of this year and FY24, the firm tells investors in a research note.